Author
Listed:
- Eric R. Braverman
(Department of Psychiatry, College of Medicine, University of Florida and McKnight Brain Institute, Gainesville, FL 32610, USA
Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA
Department of Neurosurgery, Weill-Cornell Medical College, New York, NY 10065, USA)
- Kenneth Blum
(Department of Psychiatry, College of Medicine, University of Florida and McKnight Brain Institute, Gainesville, FL 32610, USA
Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA)
- Bernard Loeffke
(Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA)
- Robert Baker
(Department of Biological Sciences, Texas Tech University, Lubbock, TX 79409, USA
Natural Science Research Laboratory, Museum of Texas Tech University, Lubbock, TX 79409, USA)
- Florian Kreuk
(Department of Clinical Neurology, PATH Foundation NY, New York, NY 10010, USA)
- Samantha Peiling Yang
(Department of Endocrinology, National University Hospital of Singapore, 119228 Singapore)
- James R. Hurley
(Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA)
Abstract
Chernobyl demonstrated that iodine-131 ( 131 I) released in a nuclear accident can cause malignant thyroid nodules to develop in children within a 300 mile radius of the incident. Timely potassium iodide (KI) administration can prevent the development of thyroid cancer and the American Thyroid Association (ATA) and a number of United States governmental agencies recommend KI prophylaxis. Current pre-distribution of KI by the United States government and other governments with nuclear reactors is probably ineffective. Thus we undertook a thorough scientific review, regarding emergency response to 131 I exposures. We propose: (1) pre-distribution of KI to at risk populations; (2) prompt administration, within 2 hours of the incident; (3) utilization of a lowest effective KI dose; (4) distribution extension to at least 300 miles from the epicenter of a potential nuclear incident; (5) education of the public about dietary iodide sources; (6) continued post-hoc analysis of the long-term impact of nuclear accidents; and (7) support for global iodine sufficiency programs. Approximately two billion people are at risk for iodine deficiency disorder (IDD), the world’s leading cause of preventable brain damage. Iodide deficient individuals are at greater risk of developing thyroid cancer after 131 I exposure. There are virtually no studies of KI prophylaxis in infants, children and adolescents, our target population. Because of their sensitivity to these side effects, we have suggested that we should extrapolate from the lowest effective adult dose, 15–30 mg or 1–2 mg per 10 pounds for children. We encourage global health agencies (private and governmental) to consider these critical recommendations.
Suggested Citation
Eric R. Braverman & Kenneth Blum & Bernard Loeffke & Robert Baker & Florian Kreuk & Samantha Peiling Yang & James R. Hurley, 2014.
"Managing Terrorism or Accidental Nuclear Errors, Preparing for Iodine-131 Emergencies: A Comprehensive Review,"
IJERPH, MDPI, vol. 11(4), pages 1-43, April.
Handle:
RePEc:gam:jijerp:v:11:y:2014:i:4:p:4158-4200:d:35111
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:11:y:2014:i:4:p:4158-4200:d:35111. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.